Blog
Ide-Cel Demonstrates Durable Responses in Relapsed/Refractory Multiple Myeloma
The CAR T-cell therapy idecabtagene vicleucel (ide-cel; Abecma) continues to
June 30, 2021
The CAR T-cell therapy idecabtagene vicleucel (ide-cel; Abecma) continues to
Alternative oxidase (AOX) has been identified as a potential therapeutic
The first CAR-T immunotherapy directed against BCMA (idecabtagene vicleucel) for
Australian company, Vaxine Pty Ltd, has developed a protein-based COVID-19
ALLO-501A is a CAR T cell-based therapy for relapsed or
According to scientists at the Medical College of Georgia, a
The development of CAR T cells is one of the
Multiple myeloma is the second most common hematological malignancy in
Locus Biosciences announced that it has completed the world’s first